Avicanna Inc., a Toronto-based biopharmaceutical company specializing in plant-derived cannabinoid products, has been awarded a U.S. patent for its topical cannabinoid gel designed to address a range of skin conditions.
The newly issued patent, No. US 12,343,315 B2, covers a formulation that combines cannabinoids with antioxidants, anti-microbial agents, and anti-inflammatory agents. According to Avicanna, the gel shows potential in treating and preventing conditions such as acne, wrinkles, rosacea, and erythema.
“We are delighted with the issuance of another USPTO patent as we continue to expand our intellectual property portfolio,” said CEO Aras Azadian. “We are excited about the potential of this patent that covers our composition that are in our commercial platforms and pharmaceutical pipeline.”
Avicanna operates across multiple segments of the cannabinoid market, including its RHO Phyto medical cannabis line, MyMedi.ca patient care platform, a pharmaceutical development pipeline targeting dermatology, chronic pain, and neurological disorders, and its Aureus Santa Marta active pharmaceutical ingredients business. The company says this latest patent strengthens its position in the dermatology space and supports ongoing commercialization efforts in Canada and international markets.
This patent marks another step in Avicanna’s push to develop evidence-based cannabinoid therapies with applications in both consumer and pharmaceutical markets.
Sponsored
